EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia

Qingli Ji, Xinwen Jiang, Xiaoqing Li, Chen Cao, Xinrui Zhang, Minran Zhou, Sai Ma, Chunyan Chen

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06841-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Qingli Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Shandong University, No. 107 Wenhuaxi Road, Jinan, 250012, China. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although KIT mutations hold significant prognostic value in acute myeloid leukemia (AML), their impact on selecting first-line treatment remains unclear. This retrospective study of 222 newly diagnosed AML patients therefore compared the efficacy of venetoclax plus azacitidine (VA) versus intensive chemotherapy (IC) in KIT-mutated AML, while also exploring the prognostic implications of KIT mutation subtypes and their role in predicting VA response. Among patients with KIT mutations, IC was superior to VA, yielding significantly longer median event-free survival (EFS) (14.5 vs. 2.4 months, p = 0.011) and overall survival (OS) (not reached vs. 9.8 months, p < 0.0001), and a higher complete remission (CR) rate (80.0% vs. 17.6%, p < 0.001). Exon 17 mutations were associated with significantly shorter EFS relative to other KIT mutations (7.3 vs. 18.8 months; p = 0.046). Moreover, among all VA-treated patients, KIT mutation was an independent adverse prognostic factor for both EFS (HR = 3.25, p < 0.001) and OS (HR = 3.31, p = 0.001). This study demonstrates the potential superiority of IC over VA in KIT-mutated AML and identifies KIT mutation as an important biomarker of resistance to venetoclax-based therapy, providing valuable guidance for first-line treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsMutationProto-Oncogene Proteins c-kitAzacitidineHumansFemaleRetrospective StudiesMaleMiddle AgedAgedAdultDisease-Free SurvivalYoung AdultSurvival Rate

Stichwörter der Autor:innen

Acute myeloid leukemiaIntensive chemotherapyKITVenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxProto-Oncogene Proteins c-kitAzacitidineKIT protein, human

Autor:innen und Institutionen

  • Department of Hematology, Qilu Hospital, Shandong University, No. 107 Wenhuaxi Road, Jinan, 250012, China.
  • Department of Hematology, Qilu Hospital, Shandong University, No. 107 Wenhuaxi Road, Jinan, 250012, China. chency@sdu.edu.cn.

Zitieren

APA

Ji, Q., Jiang, X., Li, X., Cao, C., Zhang, X., Zhou, M., Ma, S., & Chen, C. (2026). Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-06841-4

Vancouver

Ji Q, Jiang X, Li X, Cao C, Zhang X, Zhou M, et al. Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia. Annals of Hematology. 2026. doi:10.1007/s00277-026-06841-4

BibTeX
@article{Ji2026,
  author = {Ji, Qingli and Jiang, Xinwen and Li, Xiaoqing and Cao, Chen and Zhang, Xinrui and Zhou, Minran and Ma, Sai and Chen, Chunyan},
  title = {Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06841-4}
}
Kostenlos starten →